PRPO - Precipio, Inc.
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.6800 |
| Open | 0.5000 |
| Bid | 0.4701 x 2200 |
| Ask | 0.4900 x 900 |
| Day's Range | 0.4500 - 0.5100 |
| 52 Week Range | 0.4500 - 1.7000 |
| Volume | |
| Avg. Volume | 57,046 |
| Market Cap | 11.25M |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4400 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.85 |
Fair Value
Related Research
GlobeNewswirePrecipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 4,125,000 shares of the Company’s common stock and pre-funded warrants to purchase 319,445 shares of the Company’s common stock in a registered direct offering and warrants to purchase up to 8,888,890 shares of common stock at a combined purchase
- GlobeNewswire
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3NEW HAVEN, Conn., June 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that several operational improvement initiatives which commenced at the start of the year have begun to impact the cash burn and bottom line profitability. These operational efficiency improvements are independent of the contribution that the revenue continues to provide to the Co
- GlobeNewswire
Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
Panel-Based Approach of Driver Mutation Detection Proves Crucial for Patient CareNEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression (p190). While many labs only monitor previously detected muta
- GlobeNewswire
Precipio Shares Growth Catalysts For HemeScreen
Q1 Results and catalysts show promising growth trajectoryNEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s shareholders call several growth catalysts that management has been tracking. The Company believes that these catalysts could serve as positive indicators of future growth for HemeScreen revenues. Distributor rep engagement increased from 16% to 37%One of the many benefits of partnering with w
- GlobeNewswire
Precipio Announces Q1-2023 Shareholder Update Call
Conference Call to be held on May 17, 2023 at 5:00 PM ETNEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Pa
- GlobeNewswire
Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division
Customer’s pathology services annual revenues expected to exceed $1.5MNEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new pathology services customer to utilize Precipio’s diagnostic services. Based on the customer’s size and expected volume, with the addition of this and other customers, Precipio anticipates that with the addition of this customer, the Company expects to reach approximately
- GlobeNewswire
Precipio Signs Another HemeScreen™ Customer
Customer’s revenues expected at $750K at full capacityNEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new customer to bring HemeScreen™ technology into their laboratory. With each additional customer, Precipio continues to execute on its strategy, converting pipeline prospects to actual customers, and progressing towards breakeven. The company incurs virtually no additional costs for the onbo
- GlobeNewswire
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
Extension will enable the Company to execute on its growth and advance toward breakevenNEW HAVEN, Conn., April 27, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the Company to meet the required minimum $1.00 per share closing bid price of its common stock for 10 consecutive business days for continued inclusion on the Nasdaq Capital Marke
- GlobeNewswire
Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined
Q1-2023 product revenues approximately $0.76M exceeded the $0.66M combined revenue of Q3+Q4 2022NEW HAVEN, Conn., April 19, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q1-2023 product revenues have surpassed product revenues during the two prior quarters of 2022, and exceed 50% of the entire year of 2022 product revenues of $1.4M. This equals a current annualized run rate of $3M, which is more than double the total product revenues
Insider MonkeyPrecipio, Inc. (NASDAQ:PRPO) Q4 2022 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO) Q4 2022 Earnings Call Transcript April 3, 2023 Operator: Welcome to the Precipio shareholder 2022 Fourth Quarter and Year-End Shareholder Update Conference Call. All participants will be in listen-only mode. Please note that the conference is being recorded. Statements made during this call contain forward-looking statements about our business. You should not […]
Simply Wall St.Precipio Full Year 2022 Earnings: US$0.54 loss per share (vs US$0.40 loss in FY 2021)
Precipio ( NASDAQ:PRPO ) Full Year 2022 Results Key Financial Results Revenue: US$9.41m (up 6.4% from FY 2021). Net...
- GlobeNewswire
Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM ETNEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday, April 3rd at 5:00 PM ET. The call will include updates on the Company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Pre
- GlobeNewswire
Precipio Ships First IV-Cell® Order to Major US Healthcare System
Products Division revenues begin to diversify beyond HemeScreen®NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics cell culturing media, to a major US healthcare system. The healthcare system (unnamed for competitive reasons) has successfully completed the validation of the media and will begin the gradual incorporation into clinical use. About IV-Cel
- GlobeNewswire
CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
Conversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growthNEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read "revenues in Q2-2023 are now estimated to be ~50% greater than Q1-2023" rather than "~50% greater than Q1-2022". The corrected release follows: Specialty cancer diagnostics company
- GlobeNewswire
Precipio continues to sign up and onboard HemeScreen™ customers
Conversion from sales funnels developed with distribution partners alongside direct sales points to continued accelerated growthNEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) continues to convert its sales pipeline into HemeScreen customers, with an additional recently signed agreement expected to generate annualized revenues exceeding $125,000. Furthermore, this month we also expect another customer to launch an additional
GlobeNewswireThermoFisher Salesforce Votes Precipio’s HemeScreen® as “Best New Product”
HemeScreen® Technology and Product Line singled out from thousands of products distributed by Fisher Healthcare at recent National Sales Meeting Precipio receives “New Best Product” Award Precipio receives “New Best Product” Award NEW HAVEN, Conn., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) was recognized at ThermoFisher’s National Sales Meeting for the development and launch of its HemeScreen® technology. HemeScreen is distributed by Fis
- GlobeNewswire
Precipio Signs Another Major HemeScreen™ Customer
Customer’s initial annual revenue expected at $650K, $2.0M revenue at full capacityNEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced another 4-year agreement with a new customer to bring HemeScreen™ technology into their laboratory. Based on the customer’s expected patient volume, with the addition of this customer, revenues in Q1-2023 are now estimated to be approximately 200% greater than Q1-2022, and the quarterly
- GlobeNewswire
Precipio Signs Additional Major HemeScreen™ Customer
Customer to begin gradually onboarding panels in Q1-2023, potential $1.2M revenue at full capacityNEW HAVEN, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced a 4-year agreement with a new customer to bring HemeScreen™ technology into their lab. Based on volume information provided by the customer, revenues in Q1-2023 are projected to be approximately at a $250,000 run rate (an increase of ~15% to our current HemeScreen run rate
- GlobeNewswire
Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference
Poster presents findings of a study of ~1000 patient samples demonstrating superior accuracy for HemeScreen™ MPN AssayNEW HAVEN, Conn., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) presented at the annual 2022 AMP conference a poster presentation of the results of a groundbreaking study, conducted in collaboration with faculty at the University of Pennsylvania. The study, expected to be published in detail early next year, demonstrates the
- GlobeNewswire
Precipio Announces Third Quarter Shareholder Update Call
Conference Call to be held on Monday, November 14th, 2022 at 5:00 PM ETNEW HAVEN, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2022 shareholder update call on Monday, November 14th at 5:00 PM ET. The call will include updates on the Company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio
- Simply Wall St.
Precipio, Inc. (NASDAQ:PRPO) Is Expected To Breakeven In The Near Future
With the business potentially at an important milestone, we thought we'd take a closer look at Precipio, Inc.'s...
- GlobeNewswire
Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™
Adding customer segment exceeding $100M in market potentialNEW HAVEN, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a distribution agreement for HemeScreen with a major distribution partner (name withheld as per partner’s policy). Following an upcoming training program and onboarding of their national coverage, this distribution channel partner’s sales team will begin promoting and driving sales of the HemeScreen platform
- GlobeNewswire
Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales
Precipio continues to build strong team in anticipation of substantial growth in the next 12 monthsNEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), welcomes Sharon Robins as the Company’s Senior Director of Laboratory & Hospital Sales for the Product’s Division. As the Company launches HemeScreen with ThermoFisher and its 200+ member sales force, and with the goal of Thermo meeting its first-year target of $10M in revenues (a
- GlobeNewswire
Precipio Launches New 1-Step Technology for all HemeScreen Assays
New technology enables same day test results by eliminating extra confirmation stepNEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s customers using HemeScreen in their laboratory will have the option of upgrading to the 1-step assay, or remaining with the current assay. While the first generation of panels required a 2-step process that included a
- GlobeNewswire
Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & Development
Precipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributorsNEW HAVEN, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), welcomes Toni-Ann Mills as the Company’s Senior Director for Learning & Development. With a ~$0.5B market potential for HemeScreen, Precipio is preparing to mobilize all resources towards capturing significant market share. As Precipio